Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
P/S ratio for Geron Corporation (GERN)
P/S ratio as of 2023: 5080.43
According to Geron Corporation's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 5080.43. At the end of 2022 the company had a P/S ratio of 1546.14.
P/S ratio history for Geron Corporation from 1996 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 5080.43 |
| 2022 | 1546.14 |
| 2021 | 286.94 |
| 2020 | 1706.02 |
| 2019 | 562.21 |
| 2018 | 165.58 |
| 2017 | 269.11 |
| 2016 | 53.43 |
| 2015 | 21.03 |
| 2014 | 432.79 |
| 2013 | 446.71 |
| 2012 | 62.32 |
| 2011 | 71.50 |
| 2010 | 134.50 |
| 2009 | 267.91 |
| 2008 | 123.01 |
| 2007 | 52.28 |
| 2006 | 167.31 |
| 2005 | 1624.62 |
| 2004 | 320.92 |
| 2003 | 248.46 |
| 2002 | 67.19 |
| 2001 | 50.23 |
| 2000 | 46.07 |
| 1999 | 34.22 |
| 1998 | 17.29 |
| 1997 | 11.27 |
| 1996 | 12.17 |